These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39247063)

  • 1. Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic Anemia.
    Yokota H; Miyao K; Sawa M; Terakura S; Kurahashi S; Ikoma Y; Imahashi N; Morishita T; Okamoto A; Kajiguchi T; Ono T; Narita T; Kanemura N; Ozeki K; Kojima Y; Naito K; Uchino K; Tomita A; Iida H; Imoto N; Kasahara S; Inagaki Y; Nishida T; Murata M
    J Hematol; 2024 Aug; 13(4):142-149. PubMed ID: 39247063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
    Huang LF; Li L; Jia JS; Yang Y; Lin SY; Meng FK; Zhang DH; He GS
    Transplant Cell Ther; 2022 Sep; 28(9):586.e1-586.e7. PubMed ID: 35609866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
    Liu L; Han B; Zhang Y; Lei M; Liu R; Lin Z; Jiao W; Zhang F; Fu R; Zhao X; Miao M; Zhang L; Wu D
    Bone Marrow Transplant; 2024 Oct; 59(10):1449-1457. PubMed ID: 39090437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review.
    Yang Y; Ji J; Tang Z; Han B
    Front Oncol; 2021; 11():614965. PubMed ID: 33981596
    [No Abstract]   [Full Text] [Related]  

  • 5. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
    Jin Y; Li R; Lin S; Jia J; Yang Y; Zhang D; He G; Li J
    Ann Hematol; 2022 Nov; 101(11):2413-2419. PubMed ID: 36028583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia.
    Zhao Y; Yang W; Zhao X; Hu X; Hu J; Liu X; Li J; Ye L; Xiong Y; Yang Y; Zhang B; Li X; Yang X; Shi Y; Peng G; Li Y; Fan H; Zhou K; Jing L; Zhang L; Zhang F
    Front Pediatr; 2022; 10():1095143. PubMed ID: 36704148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world.
    Li R; Wang N; Chai X; Yang L; Liu K; He H; Lin S; Yang Y; Jia J; Zhang D; Gong Y; Shi J; He G; Li J
    Clin Exp Med; 2023 Oct; 23(6):2619-2627. PubMed ID: 36645546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
    Liu L; Lei M; Fu R; Han B; Zhao X; Liu R; Zhang Y; Jiao W; Miao M; Zhang F; Zhang L; Wu D
    J Hematol Oncol; 2022 Aug; 15(1):105. PubMed ID: 35962406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
    Zhang Y; Li J; Li X; Geng Q; Xie Y; Zhang G; Wei M; Ma Y
    Syst Rev; 2024 Apr; 13(1):101. PubMed ID: 38576005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of anti-thymocyte globulin-based immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent non-severe aplastic anaemia: a retrospective study from a single centre.
    Shen Y; Li Y; Liu Q; Liu W; Yu Q; Hu H; Liu S; Dong J; Xu M; Hong Y; Chen Y; Deng S; Zhuang H; Hu Z; Lin S; Shen Y; Shen J; Zhou Y; Ye B; Wu D
    Ann Med; 2023; 55(2):2271475. PubMed ID: 37871262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
    Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
    Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag in children with severe aplastic anemia.
    Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence.
    Li X; Shangguan X; Wang H; Wang Q; Zhang Y; Han B; Liu R; Zhang F; Fu R; Lin Z; Miao M; Ma X; Lei M; Wu D; Liu L
    Ann Hematol; 2024 Sep; 103(9):3483-3491. PubMed ID: 39088061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
    Hwang YY; Chan TSY; Chan FHY; Lau CWP; Luk YY; Lau GWN; Chan KP; Leung KH; Kho B; Lau JSM; Lau CK; Mak V; Yip SF; Lin SY; Sim JPY; Kwong YL
    Ann Hematol; 2022 Jun; 101(6):1163-1172. PubMed ID: 35412083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial SAA patients benefit from delayed response of IST.
    Wang T; Wang C; Liu C; Shao Z; Fu R
    Front Immunol; 2023; 14():1067977. PubMed ID: 36845107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
    Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS
    Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive therapy in severe aplastic anemia.
    Patel BA; Townsley DM; Scheinberg P
    Semin Hematol; 2022 Jan; 59(1):21-29. PubMed ID: 35491055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avatrombopag as alternative therapy for severe aplastic anemia patients who are intolerant or unresponsive to eltrombopag.
    Zhang T; Yu Q; Chen X; Yang H; Gong Y; Zhang Y; Liu X; Yang Z; Fang Y; Yan X; Zhou X; Shi J; He G
    Front Immunol; 2024; 15():1393829. PubMed ID: 39114665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study.
    Chen M; Liu Q; Gao Y; Suo X; Ding X; Wang L; Li L; Shao Y; Gao D; Sun W; Tan Y; Wang W; Ye F; Han B
    Eur J Haematol; 2023 Sep; 111(3):407-413. PubMed ID: 37271577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.